FDA Approves Real-Time Release NDAs As Agency, Early Adopters Promote PAT
This article was originally published in The Gold Sheet
Executive SummaryReal-time release has arrived with FDA approval of two NDAs that rely on process analytical technology instead of end-product testing for release to market. Merck shares its experience with PAT-based real-time release at IFPAC meeting, while FDA officials express disappointment that pharmaceutical industry has not embraced PAT more broadly. Research funding, agenda explored. Business case made. Sterility concerns raised. Legacy opportunities explored
You may also be interested in...
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.